Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

The protective effects of Mirtazapine against lipopolysaccharide (LPS)-induced brain vascular hyperpermeability

Open access

Abstract

Sepsis is mainly characterized by severe inflammation triggered by infection, and sepsis-associated encephalopathy (SAE) is defined as brain damage caused by sepsis. Disruption of the blood-brain barrier (BBB) triggered by injured brain microvascular endothelial cells (BMECs) and damaged tight junction (TJ) structure is closely associated with the pathogenesis of SAE. The present research proposed to evaluate the potential therapeutic effects of Mirtazapine, a central presynaptic α2 receptor antagonist, on LPS-induced BBB disruption. The mice were administered with normal saline and 10 mg/kg Mirtazapine for 8 consecutive days, and from day 6, the experiment group of mice received LPS for 2 days to induce SAE. We found that the increased BBB permeability, elevated concentrations of inflammatory factors in brain tissues, and downregulated zonula occludens −1 (ZO-1) were observed in LPS-stimulated mice, all of which were reversed by 10 mg/kg Mirtazapine. In the in vitro assay, bEnd.3 brain endothelial cells were treated with 1 μM LPS in the absence or presence of Mirtazapine (25, 50 μM). We found that LPS-treated cells had significantly declined transendothelial electrical resistance (TEER), increased monolayer permeability, elevated production of inflammatory factors, and downregulated ZO-1. However, 25 and 50 μM Mirtazapine ameliorated all these LPS- induced aberrations. Mirtazapine also mitigated the decreased level of NF-E2–related factor 2 (Nrf2) in LPS-challenged endothelial cells. The protective effect of Mirtazapine on endothelial permeability against LPS was significantly abolished by the knockdown of Nrf2. Collectively, we concluded that Mirtazapine exerted protective effects on LPS-induced endothelial cells hyperpermeability by upregulating Nrf2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21655979.2021.2024962

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY · PubMed Central
Figure 1. Mirtazapine attenuates LPS treatment-induced BBB disruption. The mice were weighed at day 6 before the LPS injection and weighed again at day 7, about 24 hours after the LPS injection. (a) Change in brain weight; (b) Brain/Serum weight ratio; (c) The BBB permeability to 14C-Sucrose (***, P < 0.005 vs. LPS sham group; ##, P < 0.01 vs. LPS group).
Figure 1. Mirtazapine attenuates LPS treatment-induced BBB disruption. The mice were weighed at day 6 before the LPS injection and weighed again at day 7, about 24 hours after the LPS injection. (a) Change in brain weight; (b) Brain/Serum weight ratio; (c) The BBB permeability to 14C-Sucrose (***, P < 0.005 vs. LPS sham group; ##, P < 0.01 vs. LPS group).CC BY · PubMed Central
Figure 2. Mirtazapine attenuates LPS treatment-induced elevation of cytokines in the brain. (a) mRNA level of IL-1β, IL-6, MCP-1; (b) Protein levels of IL-1β, IL-6, MCP-1 was determined (***, P < 0.005 vs. LPS sham group; ##, P < 0.01 vs. LPS group).
Figure 2. Mirtazapine attenuates LPS treatment-induced elevation of cytokines in the brain. (a) mRNA level of IL-1β, IL-6, MCP-1; (b) Protein levels of IL-1β, IL-6, MCP-1 was determined (***, P < 0.005 vs. LPS sham group; ##, P < 0.01 vs. LPS group).CC BY · PubMed Central
Figure 3. Mirtazapine elevates the expression of ZO-1 inhibited by LPS treatment in the brain. (a) mRNA level of ZO-1; (b) immunostaining of ZO-1, the representative images from each group were shown in the upper panel, the quantitative plot was shown in the lower panel (***, P < 0.005 vs. LPS sham group; ##, P < 0.01 vs. LPS group).
Figure 3. Mirtazapine elevates the expression of ZO-1 inhibited by LPS treatment in the brain. (a) mRNA level of ZO-1; (b) immunostaining of ZO-1, the representative images from each group were shown in the upper panel, the quantitative plot was shown in the lower panel (***, P < 0.005 vs. LPS sham group; ##, P < 0.01 vs. LPS group).CC BY · PubMed Central
Figure 4. Effect of Mirtazapine on LPS treatment-induced cell permeability in Bend.3 brain endothelial cells. Cells were treated with LPS (1 μM) in the absence or presence of Mirtazapine (25, 50 μM). (a). TEER on the endothelial monolayer was measured; (b) Monolayer permeability was measured using FITC-dextran permeability assay (****, P < 0.001 vs. normal mice group; ##, ###, P < 0.01, 0.005 vs. LPS treatment group).
Figure 4. Effect of Mirtazapine on LPS treatment-induced cell permeability in Bend.3 brain endothelial cells. Cells were treated with LPS (1 μM) in the absence or presence of Mirtazapine (25, 50 μM). (a). TEER on the endothelial monolayer was measured; (b) Monolayer permeability was measured using FITC-dextran permeability assay (****, P < 0.001 vs. normal mice group; ##, ###, P < 0.01, 0.005 vs. LPS treatment group).CC BY · PubMed Central
Figure 5. Effect of Mirtazapine on LPS treatment-induced cytokines in Bend.3 brain endothelial cells. Cells were treated with LPS 1 μM in the absence or presence of Mirtazapine (25, 50 μM). (a). mRNA level of IL-1β, IL-6, MCP-1 was determined; (b). Concentrations of IL-1β, IL-6, and MCP-1 (****, P < 0.001 vs. normal mice group; ##, ###, P < 0.01, 0.005 vs. LPS treatment group).
Figure 5. Effect of Mirtazapine on LPS treatment-induced cytokines in Bend.3 brain endothelial cells. Cells were treated with LPS 1 μM in the absence or presence of Mirtazapine (25, 50 μM). (a). mRNA level of IL-1β, IL-6, MCP-1 was determined; (b). Concentrations of IL-1β, IL-6, and MCP-1 (****, P < 0.001 vs. normal mice group; ##, ###, P < 0.01, 0.005 vs. LPS treatment group).CC BY · PubMed Central
Figure 6. Mirtazapine reserved the expression of tight junction proteins inhibited by LPS treatment in Bend.6. Cells were treated with LPS 1 μM in the presence or absence of Mirtazapine (25, 50 μM). (a). mRNA of ZO-1; (b). Protein expression of ZO-1. The representative blots of ZO-1 and β-actin were shown in the upper panel, the quantitative plot was shown in the lower panel (****, P < 0.001 vs. normal mice group; ##, ###, P < 0.01, 0.005 vs. LPS treatment group).
Figure 6. Mirtazapine reserved the expression of tight junction proteins inhibited by LPS treatment in Bend.6. Cells were treated with LPS 1 μM in the presence or absence of Mirtazapine (25, 50 μM). (a). mRNA of ZO-1; (b). Protein expression of ZO-1. The representative blots of ZO-1 and β-actin were shown in the upper panel, the quantitative plot was shown in the lower panel (****, P < 0.001 vs. normal mice group; ##, ###, P < 0.01, 0.005 vs. LPS treatment group).CC BY · PubMed Central
Figure 7. Mirtazapine increased the expression of Nrf2 in LPS- challenged Bend.3 brain endothelial cells. Cells were treated with LPS (1 μM) in the presence or absence of Mirtazapine (25, 50 μM) for 24 hours. (a). mRNA of Nrf2; (b). Protein of Nrf2 (****, P < 0.001 vs. normal mice group; ##, ###, P < 0.01, 0.005 vs. LPS treatment group).
Figure 7. Mirtazapine increased the expression of Nrf2 in LPS- challenged Bend.3 brain endothelial cells. Cells were treated with LPS (1 μM) in the presence or absence of Mirtazapine (25, 50 μM) for 24 hours. (a). mRNA of Nrf2; (b). Protein of Nrf2 (****, P < 0.001 vs. normal mice group; ##, ###, P < 0.01, 0.005 vs. LPS treatment group).CC BY · PubMed Central
Figure 8. Silencing of Nrf2 abolished the protective effects of Mirtazapine in endothelial permeability against LPS. Cells were transduced with Ad-viral Nrf2 shRNA, followed by stimulation with LPS (1 μM) in the absence or presence of Mirtazapine (50 μM). (a). Western blot analysis revealed a significant knockdown of Nrf2; (b). TEER value was determined; (c). Endothelial permeability (****, P < 0.001 vs. normal mice group; ###, P < 0.005 vs. LPS treatment group; $$, P < 0.01 vs. LPS+Mirtazapine group).
Figure 8. Silencing of Nrf2 abolished the protective effects of Mirtazapine in endothelial permeability against LPS. Cells were transduced with Ad-viral Nrf2 shRNA, followed by stimulation with LPS (1 μM) in the absence or presence of Mirtazapine (50 μM). (a). Western blot analysis revealed a significant knockdown of Nrf2; (b). TEER value was determined; (c). Endothelial permeability (****, P < 0.001 vs. normal mice group; ###, P < 0.005 vs. LPS treatment group; $$, P < 0.01 vs. LPS+Mirtazapine group).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 3

  1. Zhang QH, 2014, Mil Med Res, 1, 20
  2. Vedula SR, 2005, Mol Cell Biomech, 2, 105
  3. Smith WT, 1990, Psychopharmacol Bull, 26, 191

Cited by

See all 13

Metadata

Authors
Pu, Y., Zhao, L., Xi, Y., Xia, Y., & Qian, Y.
Affiliations
Shanghai University of Traditional Chinese Medicine (CN)
Corresponding author
Qian, Yiming
Venue
Bioengineered
Published
2022-01-26
Volume
13
Issue
2
Pages
3680-3693
ISSN
  • 2165-5979 (ISSN-L)
  • 2165-5987
OpenAlex
W4210619724
Cited by
12
References
42
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 1
FWCI
0.88
Type
journal article
Language
en
Open access
Locations
  • Bioengineered (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • supported by
  • Shanghai University of Traditional Chinese Medicine
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
mirtazapine, lipopolysaccharide, blood-brain barrier disruption, sepsis-associated encephalopathy, brain microvascular endothelial cells, tight junctions, ZO-1, Nrf2, endothelial permeability, neuroprotection
MeSH terms
Mirtazapine, Animals, Blood-Brain Barrier, Capillary Permeability, Lipopolysaccharides, Male, Tight Junctions, Mice, Sepsis-Associated Encephalopathy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The protective effects of Mirtazapine against lipopolysaccharide (LPS)-induced brain vascular hyperpermeability. https://app.cochat.ai/papers/10.1080/21655979.2021.2024962
The paper
Pu, Y., Zhao, L., Xi, Y., Xia, Y., & Qian, Y. (2022). The protective effects of Mirtazapine against lipopolysaccharide (LPS)-induced brain vascular hyperpermeability. Bioengineered. https://doi.org/10.1080/21655979.2021.2024962

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.